resistanceBio develops oncology drugs that focus on understanding and preventing drug resistance by mimicking the long-term evolution of cancer in a controlled environment. Their platform enables the identification of resistance pathways and the development of longer-lasting therapies, addressing the critical issue of treatment-resistant cancer that contributes to 90% of cancer mortality.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer drug resistance is a major obstacle in oncology, contributing to a high percentage of cancer-related deaths. Current drug development focuses primarily on toxicity and efficacy, often overlooking the long-term evolution of resistance, which typically takes months to develop clinically. Traditional drug testing methods, lasting only a few weeks, fail to adequately address the complex mechanisms of resistance that emerge over extended periods.
Solution
resistanceBio is developing oncology drugs by mimicking the long-term evolution of cancer in a controlled environment to understand and prevent drug resistance. The company's platform combines advanced biotechnology with long-term evolution to model cancer resistance in humans. By prioritizing resistance equally with toxicity and efficacy, resistanceBio aims to develop longer-lasting drugs, reveal resistance pathways, discover novel targets, predict clinical outcomes, and advance the right drug candidates. This approach enables the determination of new drug superiority/inferiority, faster and cheaper drug approvals, discovery of novel biomarkers, and enrollment of fewer patients to reach endpoints.
Target Audience
resistanceBio's primary customers are pharmaceutical companies and research institutions involved in oncology drug development, seeking to overcome drug resistance and develop more effective cancer therapies.
Features
- Platform that mimics long-term cancer evolution to study drug resistance.
- Ability to tune the experimental environment based on known clinical outcomes.
- Long-term evolution experiments that allow cancer to evolve resistance over extended periods.
- Creation of holistic maps of how resistance evolves.
- Identification of resistance pathways and novel drug targets.
- Prediction of clinical outcomes based on resistance evolution.